Yi Tu

Papers

Total Citations

H-Index

About

Dr. Yi Tu is a pioneering researcher in the fields of autophagy modulation and cancer therapeutics, with a particular focus on the intersection of cellular degradation pathways and immune-mediated tumor suppression. Their most-cited work, a 2021 study demonstrating that IGF1 receptor inhibition amplifies the effects of cancer drugs through both autophagy-dependent and immune-dependent mechanisms, has garnered 77 citations and represents a significant translational advance. This research emerged from a high-content, high-throughput screen of 65,000 compounds, showcasing Dr. Tu’s expertise in large-scale pharmacological discovery and their commitment to identifying clinically actionable strategies for age-associated diseases. By elucidating how IGF1R blockade synergizes with existing chemotherapies to enhance autophagic flux and recruit antitumor immune responses, Dr. Tu has provided a mechanistic framework for repurposing targeted therapies. Their work bridges fundamental cell biology with practical oncology, offering a dual-pronged approach that could improve treatment outcomes while reducing resistance. Dr. Tu’s contributions are shaping the next generation of combination therapies, making them a key voice in the ongoing effort to harness autophagy for therapeutic benefit.